Journal: Bioactive Materials

Article Title: Ribbon-shaped microgels as bioinks for 3D bioprinting of anisotropic tissue structures

doi: 10.1016/j.bioactmat.2025.12.040

Figure Lengend Snippet: μRB bioinks support multicellular patterning to model breast cancer-bone invasion at tissue interface. (A) Schematic of experimental design: bioprinting of MSCs and osteogenic differentiation to derive bone grid, followed by injection of breast cancer bioink, and monitoring invasion over time using confocal microscopy. (B) Confocal images of MSCs (red) after printing (Scale bar = 1 mm). (C) Confocal images of scaffold sections containing CellTracker-labeled MSCs (red) after 28 days of osteogenic differentiation and GFP + MDA-MB-231 cells extruded into the open pores of the grids (green) (Scale bar = 200 μm). (D) Confocal images of patterned MSC-derived bone (red) with MDA-MB-231 and MCF-7 breast cancer cells (green) after 14 days of co-culture (Scale bar = 1 mm). (E) Quantification of breast cancer cell invasion: percentage that remain in open pores vs. invading into the MSC-bone compartment (n = 5 per group). Values are reported as mean ± S.D. and p-values were determined by two-way analysis of variance (ANOVA) with Tukey's multiple comparisons test; ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.005, ∗∗∗∗p ≤ 0.001.

Article Snippet: Breast cancer cell lines MDA-MB-231 (ATCC) and MCF-7 (ATCC) were lentivirus transduced to express GFP and cultured in DMEM media (4.5 g L −1 glucose) supplemented with 10 % (v/v) fetal bovine serum and 1 % (v/v) penicillin-streptomycin.

Techniques: Injection, Confocal Microscopy, Labeling, Derivative Assay, Co-Culture Assay

Journal: Genes & Diseases

Article Title: NRG4 suppresses breast cancer metastasis via ERBB4-YAP1-mediated down-regulation of MMPs

doi: 10.1016/j.gendis.2025.101691

Figure Lengend Snippet: NRG4 inhibits breast cancer metastasis via ERBB4 phosphorylation. (A) Immunoblotting experiments indicated that rNRG4 significantly enhanced ERBB4 phosphorylation and cleavage in MDA-MB-231 cells. (B) Analysis of ERBB4 expression across different subtypes of breast cancer using the TCGA database. (C) qPCR experiments revealed the expression of ErbB4 in breast epithelial cells. (D) Kaplan–Meier survival analysis based on TCGA data demonstrated a significant positive correlation between ERBB4 expression and patient survival. (E) The survival curve illustrating the correlation between ERBB4 expression and survival among breast cancer patients. (F, G) Immunohistochemistry experiments revealed significantly lower ERBB4 expression in clinical breast cancer tissue than in adjacent tissue. (H) qPCR was used to evaluate the impact of ERBB4 overexpression on EMT. (I) Transwell experiments demonstrated the influence of ERBB4 on cell migration. (J) HE staining (left) and tumor number of lung tissues of nude mice injected with ERBB4-overexpressed MDA-MB-231 cells via the tail vein. (K) qPCR experiments demonstrated the effect of NRG4 on EMT induced by ERBB4 gene knockdown. (L) Transwell experiments revealed the effect of NRG4 on cell migration induced by ERBB4 gene knockdown. The data were presented as mean ± standard deviation. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: 4T1, MDA-MB-231, MDA-MB-453, MCF10A, MCF7, T47D, BT549, MDA-MB-468, and HEK293T cells were obtained from the American Type Culture Collection (Manassas, VA, USA).

Techniques: Phospho-proteomics, Western Blot, Expressing, Immunohistochemistry, Over Expression, Migration, Staining, Injection, Knockdown, Standard Deviation

Journal: Genes & Diseases

Article Title: NRG4 suppresses breast cancer metastasis via ERBB4-YAP1-mediated down-regulation of MMPs

doi: 10.1016/j.gendis.2025.101691

Figure Lengend Snippet: NRG4 facilitates the interaction between pERBB4 and pYAP1 to hinder the nuclear translocation of YAP1. (A) Co-IP was used to enrich for ERBB4-bound proteins, followed by silver staining of differential bands and protein mass spectrometry for identifying 162 binding proteins in 4T1 cells. (B) The number of ERBB4 binding proteins in LC/MS assays upon rNRG4 treatment for 24 h. (C) STRING analysis revealed the interaction between ERBB4 and YAP1. (D) Western blotting analysis after nuclear-cytoplasmic fractionation revealed increased pERBB4 and pYAP1 in the cytoplasm and reduced YAP1 expression in the nucleus after rNRG4 treatment. (E) Co-IP of ERBB4 in the cytoplasm of 4T1 cells treated with rNRG4, followed by immunoblotting. (F) qPCR analysis of the mRNA expression levels of EMT-related genes in MDA-MB-231 cells overexpressing YAP5SA in the presence of NRG4. (G) qPCR analysis of the expression levels of Tead subunits in 4T1 cells and MDA-MB-231 cells. (H) qPCR analysis of the mRNA expression levels of Tead1 in 4T1 cells and MDA-MB-231 cells treated with 100 ng/mL rNRG4. (I) Co-IP results demonstrated the decrease of TEAD1 and YAP1 binding by rNRG4 treatment. The data were presented as mean ± standard deviation. ∗ p < 0.05 and ∗∗ p < 0.01.

Article Snippet: 4T1, MDA-MB-231, MDA-MB-453, MCF10A, MCF7, T47D, BT549, MDA-MB-468, and HEK293T cells were obtained from the American Type Culture Collection (Manassas, VA, USA).

Techniques: Translocation Assay, Co-Immunoprecipitation Assay, Silver Staining, Mass Spectrometry, Binding Assay, Liquid Chromatography with Mass Spectroscopy, Western Blot, Fractionation, Expressing, Standard Deviation

Journal: iScience

Article Title: An atom-edged magnetic nanomotor for cancer mechanotherapy

doi: 10.1016/j.isci.2026.114994

Figure Lengend Snippet: MagGO induces tumor cell death via frequency- and mode-dependent mechanical disruption (A) TEM images of MagGO synthesized under MF. The dashed white line represents the contour edge of GO. Scale bars, 200 nm. (B) M-H curve of GO, MNP, and MagGO. (C) AFM image of MagGO and the height of GO in MagGO. Scale bars, 500 nm. (D, F, and H) Cell viability of U87 (D), MDA-MB-231 (F), and A549 (H) cells treated with MNP and MagGO under RMF and 3D MF (RMF combined with OMF stimulation) at 5 Hz. The applied field strength is 75 mT. The data were presented as the mean ± SD. (E, G, and I) Cell viability of U87 (E), MDA-MB-231 (G), and A549 (I) cells treated with MNP and MagGO under 3D MF of different frequencies. The applied field strength is 75 mT. The data were presented as the mean ± SD.

Article Snippet: Glioblastoma U87 cells, human breast cancer cell line MDA-MB-231 cells, and human lung adenocarcinoma cell line A549 cells (American Type Culture Collection, Manassas, VA, USA) were cultured at 37°C under a humidified atmosphere containing 5% CO 2 with culture medium DMEM (Hyclone) containing of 1% penicillin and streptomycin (Hyclone) and 10% fetal bovine serum (FBS, Gibco).

Techniques: Disruption, Synthesized

Journal: iScience

Article Title: An atom-edged magnetic nanomotor for cancer mechanotherapy

doi: 10.1016/j.isci.2026.114994

Figure Lengend Snippet: MagGO induces lysosomal disruption (A) CLSM images of MNPs and MagGO in U87 cells. Lysosomes were stained with LysoTracker red (red), and the MNPs and MagGO were labeled with FITC (green). Scale bars, 15 μm. (B and C) Intensity profiles (white dashed line) of signals from lysosome and MNPs/MagGO fluorescent channels in (A). (D) CLSM images of MNPs and MagGO in MDA-MB-231 cells. Lysosomes were stained with LysoTracker red (red), and the MNPs and MagGO were labeled with FITC (green). Scale bars, 15 μm. (E and F) Intensity profiles (white dashed line) of signals from lysosomes and MNPs/MagGO fluorescent channels in (D). (G) CLSM images of MNPs and MagGO in A549 cells. Lysosomes were stained with LysoTracker red (red), and the MNPs and MagGO were labeled with FITC (green). Scale bars, 15 μm. (H and I) Intensity profiles (white dashed line) of signals from lysosomes and MNPs/MagGO fluorescent channels in (G). (J) CLSM images of U87 cells transfected with the EGFP-Gal3 plasmid after MagGO treatment under 3D MF. The applied field strength is 75 mT. The duration of magnetic field application is 30 min. Scale bars, 15 μm. (K) Counts of Gal3 puncta per U87 cell ( n = 10). The data were presented as the mean ± SD. Data were analyzed by one-way ANOVA with Tukey’s post-hoc test. (L) Counts of Gal3 puncta per MDA-MB-231 cell ( n = 10). The data were presented as the mean ± SD. Data were analyzed by one-way ANOVA with Tukey’s post-hoc test. (M) Counts of Gal3 puncta per A549 cell ( n = 10). The data were presented as the mean ± SD. Data were analyzed by one-way ANOVA with Tukey’s post-hoc test. (N) Bio-TEM of lysosomal membrane morphology after mechanoporation for MagGO and MagGO+3D MF. The applied field strength is 75 mT. The duration of magnetic field application is 30 min. Scale bars, 1 μm. The dark blue arrow indicates the site of LMP, while the length of the blue arrow represents the size of the lysosomal membrane “wound”.

Article Snippet: Glioblastoma U87 cells, human breast cancer cell line MDA-MB-231 cells, and human lung adenocarcinoma cell line A549 cells (American Type Culture Collection, Manassas, VA, USA) were cultured at 37°C under a humidified atmosphere containing 5% CO 2 with culture medium DMEM (Hyclone) containing of 1% penicillin and streptomycin (Hyclone) and 10% fetal bovine serum (FBS, Gibco).

Techniques: Disruption, Staining, Labeling, Transfection, Plasmid Preparation, Membrane

Journal: iScience

Article Title: An atom-edged magnetic nanomotor for cancer mechanotherapy

doi: 10.1016/j.isci.2026.114994

Figure Lengend Snippet: MagGO primarily induces pyroptosis as the mode of cell death (A–C) CLSM images of CTSB release of U87 (A), MDA-MB-231 (B), and A549 (C) cells after MagGO treatment under 3D MF. The applied field strength is 75 mT. The duration of magnetic field application is 30 min. Scale bars, 20 μm. (D–F) The cell viabilities of U87 (D), MDA-MB-231 (E), and A549 (F) cells treated with MagGO were assessed after pre-treatment with z-VAD-FMK (10 μM), Necrostatin-1 (10 μM), 3-Methyladenine (10 μM), Ferrostatin-1 (2 μM), and MCC950 (10 nM) for 4 h, followed by exposure to 3D MF at 5 Hz for 30 min. The applied field strength was 75 mT. The data were presented as the mean ± SD. Data were analyzed by one-way ANOVA with Tukey’s post hoc test. (G and H) Quantification of IL-1β (G) and IL-18 (H) release from U87 cells for control, MagGO, and MagGO+3D MF ( n = 3). The data were presented as the mean ± SD. Data were analyzed by one-way ANOVA with Tukey’s post-hoc test. (I and J) Western blot analysis of Casp-1 (I) and GSDMD (J) in U87 cells for control, MagGO, and MagGO+3D MF.

Article Snippet: Glioblastoma U87 cells, human breast cancer cell line MDA-MB-231 cells, and human lung adenocarcinoma cell line A549 cells (American Type Culture Collection, Manassas, VA, USA) were cultured at 37°C under a humidified atmosphere containing 5% CO 2 with culture medium DMEM (Hyclone) containing of 1% penicillin and streptomycin (Hyclone) and 10% fetal bovine serum (FBS, Gibco).

Techniques: Control, Western Blot

Journal: iScience

Article Title: An atom-edged magnetic nanomotor for cancer mechanotherapy

doi: 10.1016/j.isci.2026.114994

Figure Lengend Snippet: Broad antitumor activity of MagGO across multiple tumor models (A) Schematic illustrations of in vivo anticancer therapy for MDA-MB-231 and A549 tumors. The applied field strength is 75 mT. The applied field frequency is 5 Hz. The duration of magnetic field application is 30 min. (B) The MDA-MB-231 tumor volume comparison of control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF for 14 days ( n = 5). (C) The MDA-MB-231 tumor images of control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF ( n = 5). (D) The MDA-MB-231 tumor weight of control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF ( n = 5). The data were presented as the mean ± SD. Data were analyzed by one-way ANOVA with Tukey’s post hoc test. (E) The MDA-MB-231 tumor volume of each mouse in the control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF groups for 14 days. (F) The A549 tumor volume comparison of control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF for 14 days ( n = 5). (G) The A549 tumor images of control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF ( n = 5). (H) The A549 tumor weight of control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF ( n = 5). The data were presented as the mean ± SD. Data were analyzed by one-way ANOVA with Tukey’s post hoc test. (I) The A549 tumor volume of each mouse in the control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF groups for 14 days.

Article Snippet: Glioblastoma U87 cells, human breast cancer cell line MDA-MB-231 cells, and human lung adenocarcinoma cell line A549 cells (American Type Culture Collection, Manassas, VA, USA) were cultured at 37°C under a humidified atmosphere containing 5% CO 2 with culture medium DMEM (Hyclone) containing of 1% penicillin and streptomycin (Hyclone) and 10% fetal bovine serum (FBS, Gibco).

Techniques: Activity Assay, In Vivo, Comparison, Control

Journal: iScience

Article Title: An atom-edged magnetic nanomotor for cancer mechanotherapy

doi: 10.1016/j.isci.2026.114994

Figure Lengend Snippet: MagGO induces tumor cell death via frequency- and mode-dependent mechanical disruption (A) TEM images of MagGO synthesized under MF. The dashed white line represents the contour edge of GO. Scale bars, 200 nm. (B) M-H curve of GO, MNP, and MagGO. (C) AFM image of MagGO and the height of GO in MagGO. Scale bars, 500 nm. (D, F, and H) Cell viability of U87 (D), MDA-MB-231 (F), and A549 (H) cells treated with MNP and MagGO under RMF and 3D MF (RMF combined with OMF stimulation) at 5 Hz. The applied field strength is 75 mT. The data were presented as the mean ± SD. (E, G, and I) Cell viability of U87 (E), MDA-MB-231 (G), and A549 (I) cells treated with MNP and MagGO under 3D MF of different frequencies. The applied field strength is 75 mT. The data were presented as the mean ± SD.

Article Snippet: Human: MDA-MB-231 , ATCC , Cat#HTB-26.

Techniques: Disruption, Synthesized

Journal: iScience

Article Title: An atom-edged magnetic nanomotor for cancer mechanotherapy

doi: 10.1016/j.isci.2026.114994

Figure Lengend Snippet: MagGO induces lysosomal disruption (A) CLSM images of MNPs and MagGO in U87 cells. Lysosomes were stained with LysoTracker red (red), and the MNPs and MagGO were labeled with FITC (green). Scale bars, 15 μm. (B and C) Intensity profiles (white dashed line) of signals from lysosome and MNPs/MagGO fluorescent channels in (A). (D) CLSM images of MNPs and MagGO in MDA-MB-231 cells. Lysosomes were stained with LysoTracker red (red), and the MNPs and MagGO were labeled with FITC (green). Scale bars, 15 μm. (E and F) Intensity profiles (white dashed line) of signals from lysosomes and MNPs/MagGO fluorescent channels in (D). (G) CLSM images of MNPs and MagGO in A549 cells. Lysosomes were stained with LysoTracker red (red), and the MNPs and MagGO were labeled with FITC (green). Scale bars, 15 μm. (H and I) Intensity profiles (white dashed line) of signals from lysosomes and MNPs/MagGO fluorescent channels in (G). (J) CLSM images of U87 cells transfected with the EGFP-Gal3 plasmid after MagGO treatment under 3D MF. The applied field strength is 75 mT. The duration of magnetic field application is 30 min. Scale bars, 15 μm. (K) Counts of Gal3 puncta per U87 cell ( n = 10). The data were presented as the mean ± SD. Data were analyzed by one-way ANOVA with Tukey’s post-hoc test. (L) Counts of Gal3 puncta per MDA-MB-231 cell ( n = 10). The data were presented as the mean ± SD. Data were analyzed by one-way ANOVA with Tukey’s post-hoc test. (M) Counts of Gal3 puncta per A549 cell ( n = 10). The data were presented as the mean ± SD. Data were analyzed by one-way ANOVA with Tukey’s post-hoc test. (N) Bio-TEM of lysosomal membrane morphology after mechanoporation for MagGO and MagGO+3D MF. The applied field strength is 75 mT. The duration of magnetic field application is 30 min. Scale bars, 1 μm. The dark blue arrow indicates the site of LMP, while the length of the blue arrow represents the size of the lysosomal membrane “wound”.

Article Snippet: Human: MDA-MB-231 , ATCC , Cat#HTB-26.

Techniques: Disruption, Staining, Labeling, Transfection, Plasmid Preparation, Membrane

Journal: iScience

Article Title: An atom-edged magnetic nanomotor for cancer mechanotherapy

doi: 10.1016/j.isci.2026.114994

Figure Lengend Snippet: MagGO primarily induces pyroptosis as the mode of cell death (A–C) CLSM images of CTSB release of U87 (A), MDA-MB-231 (B), and A549 (C) cells after MagGO treatment under 3D MF. The applied field strength is 75 mT. The duration of magnetic field application is 30 min. Scale bars, 20 μm. (D–F) The cell viabilities of U87 (D), MDA-MB-231 (E), and A549 (F) cells treated with MagGO were assessed after pre-treatment with z-VAD-FMK (10 μM), Necrostatin-1 (10 μM), 3-Methyladenine (10 μM), Ferrostatin-1 (2 μM), and MCC950 (10 nM) for 4 h, followed by exposure to 3D MF at 5 Hz for 30 min. The applied field strength was 75 mT. The data were presented as the mean ± SD. Data were analyzed by one-way ANOVA with Tukey’s post hoc test. (G and H) Quantification of IL-1β (G) and IL-18 (H) release from U87 cells for control, MagGO, and MagGO+3D MF ( n = 3). The data were presented as the mean ± SD. Data were analyzed by one-way ANOVA with Tukey’s post-hoc test. (I and J) Western blot analysis of Casp-1 (I) and GSDMD (J) in U87 cells for control, MagGO, and MagGO+3D MF.

Article Snippet: Human: MDA-MB-231 , ATCC , Cat#HTB-26.

Techniques: Control, Western Blot

Journal: iScience

Article Title: An atom-edged magnetic nanomotor for cancer mechanotherapy

doi: 10.1016/j.isci.2026.114994

Figure Lengend Snippet: Broad antitumor activity of MagGO across multiple tumor models (A) Schematic illustrations of in vivo anticancer therapy for MDA-MB-231 and A549 tumors. The applied field strength is 75 mT. The applied field frequency is 5 Hz. The duration of magnetic field application is 30 min. (B) The MDA-MB-231 tumor volume comparison of control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF for 14 days ( n = 5). (C) The MDA-MB-231 tumor images of control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF ( n = 5). (D) The MDA-MB-231 tumor weight of control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF ( n = 5). The data were presented as the mean ± SD. Data were analyzed by one-way ANOVA with Tukey’s post hoc test. (E) The MDA-MB-231 tumor volume of each mouse in the control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF groups for 14 days. (F) The A549 tumor volume comparison of control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF for 14 days ( n = 5). (G) The A549 tumor images of control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF ( n = 5). (H) The A549 tumor weight of control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF ( n = 5). The data were presented as the mean ± SD. Data were analyzed by one-way ANOVA with Tukey’s post hoc test. (I) The A549 tumor volume of each mouse in the control, MNP, MagGO, MNP+3D MF, and MagGO+3D MF groups for 14 days.

Article Snippet: Human: MDA-MB-231 , ATCC , Cat#HTB-26.

Techniques: Activity Assay, In Vivo, Comparison, Control